European Perspective on Multiple Myeloma Treatment Strategies in 2014

Authors: Heinz Ludwig, Pieter Sonneveld, Faith Davies, Joan Bladé, Mario Boccadoro, Michele Cavo, Gareth Morgan, Javier de la Rubia, Michel Delforge, Meletios Dimopoulos, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Philippe Moreau, Hareth Nahi, Torben Plesner, Jesús San-Miguel, Roman Hajek, Pia Sondergeld and Antonio Palumbo. The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions,the prolongationof remission duration,and extended survival becoming realistic goals, with a cure being possible…

Come and visit us at ESMO!

For yet another year, Myeloma Patients Europe will be present at the European Society for Medical Oncology Congress. The event will take place in Madrid between the 26 to 30 of September. The main congress of European Oncology is expected to meet over 16.000 attendees from over 120 countries. ESMO 2014 intends to merge state-of-the-art oncology with the latest breakthrough discoveries, from cost-effective anti-cancer treatments to best supportive care.

The latest issue of the MPE Member Update is out

The MPE Member Update is a bi-monthly summary of the activities undertaken by MPE members. It inlcudes updates on the projects and activities they have been involved in over the last two month and their plans for the nearer future. The September issue of the MPE Member Update has just been published. To check the updates by member group, please click here. If you wish to subscribe to the MPE Member Update or the MPE…

Article on cancer and depression

Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled eff ectiveness trial for the SMaRT (Symptom Management Research Trials) Oncology-2 Michael Sharpe, Jane Walker, Christian Holm Hansen, Paul Martin, Stefan Symeonides, Charlie Gourley, Lucy Wall, David Weller, Gordon Murray,

Top-line results from phase 3 focus trial of Kyrpolis®

AMGEN ANNOUNCES TOP-LINE RESULTS FROM Phase 3 FOCUS TRIAL of KYPROLIS® IN PATIENTS WITH RELAPSED AND ADVANCED REFRACTORY MULTIPLE MYELOMA THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. (Aug. 13, 2014) – Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The…